This afternoon we watched Verona Pharma rise 20.6% to a price of $104.75 per share. The Mid-Cap Pharmaceutical company is now trading -12.04% below its average target price of $119.09. Analysts have set target prices ranging from $90.0 to $170.0 per share for Verona Pharma, and have given the stock an average rating of buy.
Verona Pharma has an elevated short interest of 10.3%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 6.19. Since 10.4% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. 91.0% of Verona Pharma shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in Verona Pharma
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Perceptive Advisors Llc | 8% | 6,563,340 | $687,509,865 |
| 2025-03-31 | Janus Henderson Group PLC | 6% | 5,516,889 | $577,894,122 |
| 2025-03-31 | Darwin Global Management, Ltd. | 5% | 3,923,204 | $410,955,619 |
| 2025-03-31 | Frazier Life Sciences Management, L.P. | 4% | 3,457,850 | $362,209,787 |
| 2025-03-31 | Eventide Asset Management LLC | 3% | 2,893,437 | $303,087,525 |
| 2025-03-31 | RTW Investments LP | 3% | 2,848,800 | $298,411,800 |
| 2025-03-31 | NEA Management Company, LLC | 3% | 2,688,565 | $281,627,183 |
| 2025-03-31 | Summit Partners Public Asset Management LLC | 3% | 2,323,115 | $243,346,296 |
| 2025-03-31 | Wellington Management Group, LLP | 2% | 2,131,502 | $223,274,834 |
| 2025-03-31 | Price (T.Rowe) Associates Inc | 2% | 1,866,280 | $195,492,830 |
For these reasons, we consider that the Verona Pharma is the subject of positive market sentiment.
